Aysham Chaudry
Research Subjects
Aysham Chaudry has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Tsering Dolkar
Internal Medicine, One Brooklyn Health (OBH) Interfaith Medical Center, Brooklyn, USA
2 shared publications - Alix Dufresne1 shared publication
- Ferdous Salauddin1 shared publication
- Henry Mann
Internal Medicine, One Brooklyn Health System Interfaith Medical Center, Brooklyn, USA
1 shared publication - Madhumati Kalavar
Divisions of Hematology and Oncology, Brooklyn, N.Y., USA
1 shared publication Muhammad H. Dogar
Internal Medicine/Cardiology, One Brooklyn Health (OBH) Interfaith Medical Center, Brooklyn, USA
1 shared publication
Latest Publications
- Open Access
- 8 November 2022
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31216
Coronavirus Disease 2019 Associated Acute Myocardial Infarction and Atrial Fibrillation: A Case Report
In the last two years since the inception of the Coronavirus pandemic, there have been a myriad of reports and studies related to Coronavirus disease 2019 (COVID-19). We present a unique case of COVID-19 associated with both acute myocardial infarction and new-onset atrial fibrillation (AFIB) in an elderly lady which is the first reported case to the best of our knowledge. The patient was symptomatic with acute COVID-19 and developed a type 2 myocardial infarction with new-onset AFIB. The patient also developed sepsis which may have contributed to the development of AFIB.
- 8 November 2022
- Published by Springer Nature in Cureus
- Vol. 14 (11) , e31216
Open AccessCoronavirus Disease 2019 Associated Acute Myocardial Infarction and Atrial Fibrillation: A Case Report
In the last two years since the inception of the Coronavirus pandemic, there have been a myriad of reports and studies related to Coronavirus disease 2019 (COVID-19). We present a unique case of COVID-19 associated with both acute myocardial infarction and new-onset atrial fibrillation (AFIB) in an elderly lady which is the first reported case to the best of our knowledge. The patient was symptomatic with acute COVID-19 and developed a type 2 myocardial infarction with new-onset AFIB. The patient also developed sepsis which may have contributed to the development of AFIB.
- Open Access
- 19 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e27007
Warfarin Failure in a Patient With Chronic Thromboembolic Pulmonary Hypertension: A Case Report and Literature Review
Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension caused by chronic venous thromboembolism (VTE). Venous thromboembolism (VTE) manifests as deep vein thrombosis (DVT), progressing to pulmonary embolism (PE). Pulmonary endarterectomy (PEA) is the preferred therapeutic option as it provides vascular disobliteration. Long-term anticoagulation with warfarin or direct oral anticoagulants (DOACs) is recommended for patients at risk for recurrent DVT in poor surgical candidates. However, treatment failure remains a concern. We present a patient who had VTE despite long-term anticoagulation with warfarin who had failed treatment and developed VTE with a therapeutic dilemma to continue anticoagulation despite supratherapeutic international normalized ratio (INR).
- 19 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e27007
Open AccessWarfarin Failure in a Patient With Chronic Thromboembolic Pulmonary Hypertension: A Case Report and Literature Review
Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension caused by chronic venous thromboembolism (VTE). Venous thromboembolism (VTE) manifests as deep vein thrombosis (DVT), progressing to pulmonary embolism (PE). Pulmonary endarterectomy (PEA) is the preferred therapeutic option as it provides vascular disobliteration. Long-term anticoagulation with warfarin or direct oral anticoagulants (DOACs) is recommended for patients at risk for recurrent DVT in poor surgical candidates. However, treatment failure remains a concern. We present a patient who had VTE despite long-term anticoagulation with warfarin who had failed treatment and developed VTE with a therapeutic dilemma to continue anticoagulation despite supratherapeutic international normalized ratio (INR).